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Dear Reader,
This year’s Children’s Mercy Cancer
Center annual report focuses on
the most common solid tumor of
childhood: neuroblastoma. It is
a diverse tumor and remains a
significant challenge in many ways.
Neuroblastoma varies from a
tumor diagnosed in a newborn that
spontaneously regresses if the child
can survive the first few months, to
a tumor occurring in older toddlers
that remains one of our most
difficult-to-cure childhood cancers.
To achieve that cure requires some
of the most intensive therapy we
subject children to.
In addition, neuroblastoma
refers to the malignant
group of neuronal tumors
in childhood. We still see
many significant benign
neuronal tumors, such as
ganglioneuroma and
ganglioneuroblastoma,
that can also cause
havoc in the child
due to their
space-occupying
tendencies
and associated
metabolic
derangements.
Curative therapy
requires advanced
pathologic and
genetic techniques
to guide the choice
of therapeutic
options, as well as
advanced radiologic
scanning and nuclear
medicine capabilities
to identify the wide
metastatic spread of
this tumor to guide
therapy. Once therapy
is initiated, the intensity
of chemotherapy
needed has few
equals in oncology, and
comprehensive supportive
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care is necessary to assist the child’s
ability to tolerate not just a single
course, but a year and a half of
therapy.
Neuroblastoma is known as an
infiltrative tumor presenting great
challenges to the surgeon who,
after chemotherapy has induced
shrinkage, must then attempt to
remove the remaining tumor often
surrounding major organs and
vessels, such as the aorta. The child
must then endure not one, but two
bone marrow transplants, quickly
followed by radiation therapy to
the prior sites of tumor. This
is then followed by months
of intensive antibody and
associated immunotherapy,
which many centers simply
cannot provide outside
the ICU. Only then can a
parent and the child
enter into the long
waiting game of
monitoring for
possible relapse
(which remains
the greatest
cause of failure)
and for the
long-term side
effects.
Still, there is
hope. New
methods of
treatment have
been tested in the
majority of children with
neuroblastoma and we
are seeing tremendous
advances: in the late
1980s as few as 10
percent could be expected
to survive this tumor;
today up to 50 to 60
percent are surviving four
years or more. Through
local and collaborative
research endeavors, new
discoveries are moving
from the test tube to the

bedside and, hopefully, someday
to the large national trials that have
brought us so far.
I am pleased to introduce you
to this year’s annual report that I
hope illustrates to you the breadth
and depth of research, diagnostic,
clinical and psychosocial resources
available in the Children’s Mercy
Cancer Center. Today’s child with
neuroblastoma has a much greater
chance of cure, and like those
children of 20 to 30 years ago,
today’s child with neuroblastoma is
helping make the future outcomes
for children with this dreaded
cancer so much more hopeful than
even today.
Thank you to our donors and
volunteers whose philanthropic
support sustains our work. Thanks,
too, to our staff and and especially
our children and their families for
working so hard and for sacrificing
so much to make the fear of this
cancer someday a thing of the past.
Yours in hope,

Alan S. Gamis, MD, MPH
Professor of Pediatrics, 		
University of Missouri-Kansas City
School of Medicine
Adjunct Professor of Pediatrics,
University of Kansas School of Medicine
Co-Director, Drug Discovery and Delivery
Experimental Therapeutics, 		
NCI-designated KU Cancer Center
Section Chief, Oncology, 		
Children’s Mercy Kansas City
Associate Division Director, Division of
Hematology / Oncology / Bone Marrow
Transplantation, 			
Children’s Mercy Kansas City

Children’s Mercy
Cancer Center
The Children’s Mercy Cancer Center is a multispecialty, multidisciplinary center of excellence providing state-of-the-art
care for children with cancer. All children with all types of cancer are seen in the center by cancer and other pediatric
specialists. The center brings together caregivers and researchers in various programs focused on specific types of
cancers, specific types of therapy and specific types of patients. Through these focused programs, coordinated patient
care and coordinated research can better take place. These programs synergistically work with each other further to
strengthen the clinical and research efforts for our patients today and tomorrow.
The programs within the Children’s Mercy Cancer Center are listed below along with their program directors. The
programs include the cancer specialists (oncologists and radiation therapists), the appropriate medical and surgical
specialties for that tumor or therapy, the pathology, laboratory, and radiologic specialists critical to that program’s
focus, specialty advanced practice providers, pharmacologists, psychosocial professionals, along with our research
scientists and research administrative personnel.
Specialties represented in the Children’s Mercy Cancer Center include: oncology, radiation therapy, surgery (including
general, neuro-, orthopaedic, transplantation, and ENT), pathology and laboratory medicine, cytogenetics/genomics,

Tumor-focused Comprehensive
Programs

Therapy and Diagnostic-focused
Programs

Leukemia / Lymphoma - Keith August, MD, MSc
Brain Tumor - Kevin Ginn, MD

Experimental Therapeutics - Keith August, MD, MSc
(Interim Director)

Bone & Soft Tissue Sarcoma - Kate Chastain, MD

Bone Marrow Transplantation - Rakesh Goyal, MD

Liver Tumor - Michelle Manalang, MD

Cellular Therapy – G. Doug Myers, MD

Histiocytoses - Allyson Hays, MD

Cancer Genomics - Erin Guest, MD

Children’s
Mercy
Cancer
Center
Tumor-focused Clinical Programs/
Clinics
Skin Cancer - Maxine Hetherington, MD
Vascular Tumors - Shannon Carpenter, MD, MS

Tumor Biorepository - Erin Guest, MD and
Alex Kats, MD (Pathology)

Population-focused Programs
Survive & Thrive Program for Long-term Survivors Joy Fulbright, MD
Hispanic Oncology Program
- Terrie (Tristan) Flatt, DO
Adolescent and Young Adult Cancer
- Joy Fulbright, MD
Family-Centered Care Program
- Kristin Stegenga, RN, PhD
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endocrinology, gastroenterology,
neurology, rehabilitation medicine,
genetics, infectious diseases,
palliative care and ethics. These
specialists not only participate
intimately in the Cancer Center
programs, but also work together
with Oncology on the Medical Staff’s
Cancer Care Committee, which
provides oversight for the hospital’s
cancer services. Children’s Mercy is
an American College of Surgeon’s
Commission on Cancer accredited
children’s cancer center.
The Cancer Center works in
partnership with other cancer and
research centers in the Kansas City
region. Among these, Children’s
Mercy in 2015 became one of three
consortium members, along with
the KU Cancer Center (for adults)
and the Stowers Medical Research
Institute (for basic sciences), to
comprise the NCI-designated
KU Cancer Center, the only such
center in the region. Since 2010,
Children’s Mercy has been the
primary and only pediatric member
of the KU Cancer Center’s Midwest
Cancer Alliance. Children’s Mercy
is a 25-plus year member of the
National Cancer Institute’s Children’s
Oncology Group (COG), the only
such institution in the region.
Children’s Mercy is an American
College of Surgeon’s Commission on
Cancer accredited children’s cancer
center – one of only 11 nationwide.
As noted, children of all ages,
birth to 21, and with every type of
cancer come to Children’s Mercy.
With our expanding partnerships,
our researchers and clinicians
are ensuring that not only are
our patients transitioned to adult
providers as they age, but that
we still participate in their care
for years to come, as well as to
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provide consultation for those young
and older adults with cancers for
which pediatric cancer regimens
offer the best chance for long-term
cure. Every patient has a primary
oncologist, along with a primary
advanced practice nurse and a
primary social worker coordinating
every aspect of their care. Every
discipline critical to a child’s health
is readily available. These include
nutrition, pharmacology, Child
Life, psychology, physical and
occupational therapy and others.
The Cancer Center provides two
large units dedicated entirely to
children with cancer and blood
disorders: the 38-bed entirely hepafiltered inpatient unit, which includes
a 15-bed BMT unit; and the 14-room
infusion bay plus 18 exam room
Outpatient Clinic, all staffed with
specialty trained nurses.

Children of
all ages,
birth to 21,
and with
every type of
cancer come
to Children’s
Mercy.

The inpatient teams are all staffed
by board-certified
hematology/
oncology
physicians,
specialty fellows,
residents and
advanced
practice nurses.
Hematology/
Oncology
specialists are on
site around the
clock, 365 days a
year.
Once completing their care, children
and their families are monitored
closely for recurrence and the
late effects of therapy, eventually
moving onto our Survive and Thrive
program before transitioning to our
Adult Survivors of Childhood Cancer
program. •

Ibrahim Ahmed, DSc, MD

Division of Hematology / Oncology /
Bone Marrow Transplantation
The primary specialists for most children with cancer reside within the Section of Oncology, part of the Division of
Hematology/Oncology/Bone Marrow Transplantation at Children’s Mercy Kansas City. The leaders in the division
include: Gerald Woods, MD, Division Director; Shannon Carpenter, MD, MSc, Associate Division Director and
Section Chief of Hematology; Alan Gamis, MD, MPH, Associate Division Director and Section Chief of Oncology;
and Rakesh Goyal, MD, Associate Division Director and Section Chief of Bone Marrow Transplantation.

The division has 29 boardcertified or board-eligible
hematology/oncology specialists;
12 within Oncology, six within
Hematology, four in Bone Marrow
Transplantation, and seven
comprising the division’s inpatient
Attending Hematology/Oncology
Hospitalist group. In the 20162017 academic year, the division’s
Fellowship Program has seven
in training who have previously
completed a pediatric residency;
two in each of a three-year program
and one research scholar in a fourth
year. The division also is home to 36
advanced practice nurses and one
physician’s assistant who each work
individually with physicians or on
inpatient teams. There are 10 social
workers for the division’s children.
Research is a large focus of the
division, which includes nearly
100 open trials at any given time,
the division has 18 professionals
dedicated to ensuring that research,
clinical and laboratory, is done
properly, effectively and safely for
our patients and researchers.

Rounding out the division are
our administrative assistants,
supporting this large group of
clinicians, researchers and ancillary
care staff.

board-eligible hematology/oncology
specialist; and a hematology/
oncology attending, fellow and
advanced practice nurse are
available on call 24/7.

Most division members’ offices are
located in the recently refurbished
Black & Veatch building, while
others are in the clinic inside the
Hall Family Outpatient Clinic, both
on the Children’s Mercy Adele Hall
Campus.

Outpatients are seen weekdays and
on Saturdays for labs, evaluations,
chemotherapy, transfusions or
procedures in either the dedicated
14 infusion bay/18 exam room
Hematology/Oncology clinic, or
in the 4 Henson infusion room.
Patients see their own primary
hematology/oncology provider
teams as outpatients and nursing
in the clinic are, when possible, is
also cohorted to ensure continuity
for each patient. The Hematology/
Oncology Clinic is also fully staffed
by a highly selective nursing and
ancillary care staff. On floor and in
clinic are ever-present additional
ancillary care providers who are
dedicated to the hematology/
oncology patient population and
include pharmacists and doctorates
of pharmacy, nutritionists, Child
Life specialists, chaplains and
psychologists. •

During the weekday, five services
provide coverage to the division
inpatients: General Hematology/
Oncology service; Attending
Hematology/Oncology Hospitalist
service; Chemotherapy service;
Bone Marrow Transplant service,
and the Inpatient Coagulation
Consultative service. On weekends,
there are three inpatient services.
Most patients are admitted to one
of the fully hepafiltered, positive
pressure 38 single-bed rooms on
the Hematology/Oncology/Bone
Marrow Transplant floor (4 HensonHall). There is the 24/7 in-house
presence of a board-certified/
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Glenson Samuel, MD
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Cancer Registry
Review-2015
Following each patient’s cancer
status is a very important part of
Cancer Registry data collection.
Knowing outcomes of each cancer
patient can assist care providers
with determining best treatment
methods and other long-term
effects of cancer treatment.
Therefore, follow-up letters inquiring
about a patient’s cancer status are
sent out yearly. Parents and older
patients are encouraged to contact
the registry by secure email at
cancerregistry@cmh.edu to discuss
follow-up.

The Cancer Registry at Children’s
Mercy Kansas City plays a vital part
in the surveillance of cancer in our
pediatric population. The Cancer
Registry is a HIPPA-compliant
confidential database comprised
of malignant cancers, benign brain
tumors and other specified benign
cancers. The database is operated
under the guidance of the Cancer
Care Committee with accreditation
approval maintained by the
American College of Surgeons
Commission on Cancer. Data
collected, which includes diagnosis,
treatment, recurrence and survival,
is standardized for state and
national comparisons.

Of these patients, there were 190
patients who were diagnosed with
malignancies and benign central
nervous system tumors. There
were 25 patients added to the
registry as having benign reportable
conditions. These conditions
are collected at the request of
the Cancer Care Committee for
surveillance purposes and are not
required to be reported outside our
facility. Please see the Frequency by
Diagnosis chart for a breakdown of
cancers. •

During 2015, the Cancer Registry
added 215 patients to the database.

Frequency of Diagnosis by Disease Type
2015
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Neuroblastoma: Overall 5-Year Survival by Stage - 2005-2015
Kaplan - Meier

100

5-Year Stages I, II, III, IVS
Survival, 100%

90

Percent Surviving

80
70

3-Year Stage IV
Survival, 78.85%

60

5-Year Stage IV
Survival, 69.27%

50
40
30
20
10

Neuroblastoma Stage I 2005-2015 (N=16)
Neuroblastoma Stage II 2005-2015 (N=11)
Neuroblastoma Stage IV 2005-2015 (N=48)
Neuroblastoma Stage IVS 2005-2015 (N=11)
Neuroblastoma Stage III 2005-2015 (N=16)

0
0

1

2

3

Years After Diagnosis

4

Patient from 1 Iowa county
207 miles - Farthest distance
from Children’s Mercy

5

IOWA
Geographic Locations of
Neuroblastoma Patients
at Diagnosis

KANSAS
MISSOURI
Patients from 19 Kansas counties
268 miles - Farthest distance from Children’s Mercy

Solid Tumors 2015

Patients from 16 Missouri counties
194 miles - Farthest distance from
Children’s Mercy

Sites of Neuroblastoma Origin
2005-2015
Head/Neck
1

Kidney
Tumors
Bone
5 17.95%
Tumors
4

Not
specified
9

17.95%
Abdomen,
Adrenal Gland
37

Thoracic
18

43.59%

Neuroblastoma
10

43.59%

25.64%
Miscellaneous
Tumors
39

12.82%
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Rhabdomyosarcoma
3

25.64%

Abdomen,
extra-adrenal or NOS
12.82%
36

Neuroblastoma Stage at Diagnosis
2005-2015

Neuroblastoma Frequency by Race / Ethnicity
2005-2015

IV-S

17.95%

I
16%
17.95%

11%

Black
6%

Hispanic/Black

43.59%

1%

Hispanic/White

II

43.59%

11%

4%

White
85%

Other

25.64%

1%

Vietnamese
2%

47%

Asian Indian
or Pakistani, NOS

12.82%

25.64%
III

IV

15%

12.82%

1%

Cancer and Neuroblastoma Facts
700

children are diagnosed with
neuroblastoma annually.

APPROXIMATELY

16,000

children are diagnosed with
cancer in the U.S. each year.

90

PERCENT
of all children and teenagers
fighting cancer n the U.S.
are cared for at a
Children’s Oncology Group institution.

CHILDREN’S MERCY KANSAS CITY HAS

200+

new oncologic diagnoses each year, or

four children

are newly diagnosed with cancer each week.

36

PERCENT
of neuroblastomas present
with high-risk disease.

60 PERCENT OF CHILDREN
enroll in a clinical trial
compared with less than

5 PERCENT OF ADULTS.
TEENAGERS

treated at a pediatric cancer center
with pediatric cancer protocols
are more likely to be cured
than those treated elsewhere and on
protocols designed for adults.

THE THREE HALLMARKS OF CANCER:

uncontrolled duplication of tumor cells growing into tumor masses
loss of the cell's original function, leaving a nonfunctional tumor
mass occupying space which our normal cells or organs require
to keep us alive
failure to remain in its original location, leading to distant tumor
metastases occupying critical space throughout the body.
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Neuroblastoma is the most common solid tumor malignancy in
children outside the central nervous system, and trails only the
leukemias, brain tumors and lymphomas in frequency of diagnosis.
Compared to other pediatric solid tumors, neuroblastoma is unique.
This disease displays a continuum of behaviors ranging from a rather
indolent tumor that spontaneously regresses to an extremely malignant
tumor that relentlessly progresses. Neuroblastoma is also in a spectrum
of pediatric neuronal tumors from the most benign, ganglioneuroma,
to the increasingly aggressive ganglioneuroblastoma, to the malignant
neuroblastoma.
Each year in the United States more than 700
children are diagnosed with neuroblastoma
(8 to 10 percent of all pediatric cancers). The
median age of occurrence is 19 months. This
is the most common solid tumor in those less
than 1 year of age. It is very rare after the age
of 10. Slightly more boys than girls (1.2 to 1) are
diagnosed.

Patients with Neuroblastoma by Gender
2005-2015

17.95%

43.59%
Male
50.5%

Female
49.5%

Neuroblastoma is most often sporadic,
25.64%
however, a small subset, less than 2 percent,
has a family history of the disease. Familial
neuroblastoma frequently occurs at a younger
12.82%
age and may present with multiple primaries,
often bilaterally adrenal-based. These are
typically either due to an ALK (anaplastic lymphoma kinase) or PHOX2B germline mutation,
the latter associated with Hirshprung’s. Both the benign and the malignant forms can occur
within the same family pedigree. It is also known to occur in children with neurofibromatosis,
Beckwith-Wiedeman, Li-Fraumeni, and Noonan’s syndromes, though these only comprise a
small percentage of all children who develop neuroblastoma.
Frequency of Neuroblastoma Diagnosed by Year
2005-2015
2015
9

2014

2005
7 17.95%
2006
10

11

2007

43.59%
2013

12

8

25.64%
2008

2012

10

14

2011
7

2010
12.82%
7
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2009
6

Neuroblastoma can arise from any point
along the sympathetic nervous system
including the paraspinal ganglia or the adrenal
medulla. The presentation often indicates
the aggressiveness of the disease. The tumor
may be palpated in an asymptomatic child at
a well child check or the child may have vague
symptoms such as achiness and constipation.
It is only after these complaints persist or worsen
that additional work-up is prompted. Asymptomatic
children more likely have a lower stage or less
aggressive neuroblastoma and may initially be
thought, prior to scans, to be one of the other
abdominal masses seen in pediatrics such as Wilms

0%

10%

6-12 months

0-6 months
26%

20%

7%
12-18 months

5%

Age Groups at Diagnosis

Distribution of New Patients with Neuroblastoma
at Children’s Mercy by Age at Diagnosis
2005-2015

30%

18 months-3 years
29%

40%

50%

60%

3-5 years
19%

70%

80%

>5 years
15%

90%

100%

Percentages of all children with neuroblastoma diagnosed

tumors, where patients present less
ill-appearing.
Conversely, children may present
constitutionally very ill. They may
appear emaciated, pale, febrile
and with the classic raccoon eyes
finding that includes proptosis
and periorbital ecchymosis due to
retrobulbar metastases. These are
all common in high-risk patients.
Intraspinal extension through the
neuroforamina (often seen as
dumbbell lesions on CT or MRI) may
present with decreased strength or
loss of lower extremity function. The
presence of neurologic symptoms
is considered an oncologic
emergency. Patients with extensive
bone marrow disease may
present with pain and symptoms
associated with pancytopenia
such as fatigue, pallor, bleeding
or frequent infections. Two unique
paraneoplastic constellations of
symptoms are seen in a minority of
children with neuroblastoma. The
first is the opsoclonus-myoclonus
ataxia syndrome seen in 4 percent
of children (symptoms include
jerky random eye movements
and poor coordination of muscles)
felt to be due to an antibody-

mediated reaction in the central
nervous system. This is typically
associated with low-stage favorable
risk neuroblastoma, but requires
specific systemic therapy to counter
these symptoms. Children may
have long-term neurologic and
cognitive deficits from this. The other
is the Vasoactive Intestinal Peptide
(VIP) - Watery Diarrhea syndrome
due to the aberrant secretion of
VIP hormone from these tumors
which often presents as failure to
thrive. This too most often arises
in the benign neuronal tumors or
low-stage favorable neuroblastoma
and resolves rapidly with surgical
removal of the tumor.
Vital sign changes are seen as
a result of pain or bone marrow
involvement. Fevers may be
secondary to an infectious process
due to leucopenia, or arise from the
disease process itself. Hypertension
is present in about 15 percent
of children with neuroblastoma
and is thought to be a result of
renovascular compression or
elevated circulating catecholamines.
Urine catecholamines, homovanillic
acid and vanillylmandelic acid
obtained by spot urine samples

are elevated in 90 percent of
neuroblastoma patients at
diagnosis, but in only about half
of the children who have relapsed
disease.
Metastatic extension occurs via
the lymphatic and hematogenous
systems. Common sites of
metastases are the lymph nodes,
bone, bone marrow, liver and skin.
At diagnosis, a thorough metastatic
evaluation is imperative to obtain
important staging information
that is key to treatment planning.
The various imaging modalities
necessary are typically available
only at pediatric institutions such as
Children’s Mercy or large universitybased hospitals. Additionally,
because of the young age of
children with neuroblastoma and
those who have thoracic primaries,
anesthesia is often required.
Neuroblastoma can be visualized
by plain film radiographs, computed
tomography (CT) scans (both with
and without contrast), magnetic
resonance imaging (MRI) and
radionuclide imaging such as
bone scintigram, positron emission
tomography (PET) and I-123
metaiodobenzylguanidine (MIBG).
The imaging modalities of choice
and their combination is based
on several factors, including the
child’s age, current state of illness,
presumed staging, and may be
obtained in a sequential order to
build upon current radiographic
findings, such that a PET may be
obtained if the MIBG is negative,
or an MRI of the spine if the CT is
concerning for intraspinal extension.
Timely access to all these imaging
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modalities is imperative and are
available at Children’s Mercy with
radiation exposures calibrated to a
child’s size.
Radiographic findings aid in
determining a child’s disease
stage not only by the presence
or absence of metastases, but
with certain “imaging defined risk
factors” (IDRF). IDRFs are risk factors
related to localization, involvement
of vital organs and structures, and
likelihood of surgical resection.
They are standardized by the
International Neuroblastoma Risk
Group (INRG) staging system, and
include encasement of the aorta
or invasion of a renal pedicle for
example.
Risk is also dependent on the
patient’s age, tumor stage (see
chart) and biologic features of
the International Neuroblastoma
Pathology Classification (INPC).
This pre-therapy classification
requires experienced pathologic
determination of histology (i.e.,
stroma rich or poor, degree of
neuroblastic maturation, and
mitotic-karyorrhexis index) and
genomics such as MCYN status,
DNA ploidy, loss of 1p, loss of
11q, and gain of 17q. In general,
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is the only COG center between
Denver, Colo., and Columbia, Mo.,
and Omaha, Neb., and Oklahoma
City, Okla. Our membership ensures
that the most advanced therapy
is available here in the Kansas
City area as it is in other centers
across the country. Children’s
Mercy also participates in other
early phase consortia, as well as
bringing novel therapies such as
Chimeric antigen receptor T (CAR
T) cell therapy to our children who
have relapsed disease. Through
inclusion and participation in clinical
The INRG (which is replacing the
and laboratory research trials
historic International Neuroblastoma
[See Research], children here at
Staging System (INSS)) divides
Children’s Mercy have access to the
tumors into four stages, L1, L2,
therapies that are becoming the
M and Ms to allow data from
standard of care for the future. Now,
U.S.-based cooperative group
as the pediatric consortium partner
clinical trials such as the Childrens
in the KU Cancer Center (with
Oncology Group (COG) to be
Stowers and KU), Children’s Mercy
compared to other international
is a part of the NCI Cancer Center
trials.
network, with even more access to
NIH-supported
Description
INRG Stage
basic and
translational
L1
Localized tumor not involving vital structures as defined by the list of
image-defined risk factors* and confined to one body compartment.
research, in
Locoregional tumor with presence of one or more image-defined
L2
addition to our
risk factors.
long-standing
Distant metastatic disease (except Ms).
M
involvement
Metastatic disease in children ounger than 18 months with
Ms
in NCImetastases confined to skin, liver and/or bone marrow (bone
marrow involvement should be limited to < 10 percent of total
sponsored
nucleated cells on smears or biopsy). Primary tumor may be L1 or L2
clinical
as defined above.
research.
tumors with whole
chromosomal
gains or
losses and/
or hyperdiploid
content have
favorable
outcomes,
whereas those
with structural
or segmental
chromosomal
abnormalities have poor outcomes
[See Pathology, Cytogenetics].

COG is a cooperative group of
children’s cancer specialists
sponsored by the National
Cancer Institute and oversees
trials for pediatrics. Children’s
Mercy, a member of the NCI COG
organization since the 1980s, is
one of the larger participating COG
cancer centers in the country. It

Based on the above evaluations at
diagnosis, neuroblastoma can really
be considered to be two distinct
cancers with very different chances
of cure. At diagnosis, patient
therapy is determined by the risk
of relapse, high risk and non-high
risk, to both maximize the chance of

cure and minimize the risks. Clinical
(age, stage) and biologic (tumor
pathology, genetics) characteristics
present at diagnosis identify cohorts
of non-high-risk neuroblastoma
patients. This non-high or good
risk group may be further divided
into those in whom exposure to
chemotherapy or surgery may be
unnecessary and simply observed,
often with spontaneous regression
of their tumors, or to the other
good risk patient group that may
need only minimal therapy, two to
eight cycles based on biology and
response, to also achieve an overall
survival in excess of 90 percent.
Children with
high-risk
neuroblastoma
conversely
Low
Observation +/- Surgery
receive an
Risk
aggressive
year and half
of therapy
consisting of a
Intermediate
Chemotherapy
+/- Surgery
Risk
complex schedule
of surgery,
chemotherapy,
tandem bone
High
marrow
ImmunoChemoSurgery BMT #1
Radiation
Tx
therapy
BMT #2
Risk
transplantation,
radiation and
immunotherapy.
The high-dose
chemotherapy cycles require
hospitalization and intensive
supportive care. Surgery, most
often employed after chemotherapy
but before transplant, requires
an experienced pediatric surgeon
in order to achieve the greatest
possible removal of remaining
tumor [See Surgery]. Bone marrow
General Approaches
to Neuroblastoma Care

transplantation, involving high
doses of chemotherapy and stem
cell infusion, is then employed and
requires weeks of hospitalization
in specialized BMT units [See Bone
Marrow Transplantation]. Radiation
targeting and dosing is based
upon location and response serially
assessed throughout treatment,
and which is administered by
pediatric radiation therapy
physicians after bone marrow
transplantation [See Radiation]. After
radiation, a combination of specific
immunologic agents including an
antibody specifically developed
for neuroblastoma (anti-GD2) is
administered and requires intensive
supportive care while infusing
each month. Finally, this unique
tumor is treated with an agent,
cis-retinoic acid, that functions
best at the end of therapy to mop
up any remaining cancer cells
by causing their maturation into
mature neuronal cells incapable of
dividing out of control. This complex
schedule of care has slowly
been developed through years of
research to improve the outcome
for this high-risk group of children
from 10 percent in the 1980s to now
50 to 60 percent in 2016. Multiple
pediatric subspecialty experts that
are part of an experienced team
[See Advanced Practice Nursing
& Cancer Center] are required to
manage this complex care and are
available at Children’s Mercy.
The intensity, overall length of
therapy, and high-risk prognosis all
require a strong multidisciplinary
team that addresses pharmacologic
individualized dosing and
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interactions, nutrition, physical
conditioning, pain control and
psychosocial needs of the patient
and family. This is accomplished at
Children’s Mercy through embedded
and specialized staff in nursing,
pharmacology, nutrition, physical
and occupational therapy, social
work, child life, and psychology
within the Cancer Center dedicated
to the children with cancer.
Responses that impact therapeutic
decisions are categorized based
on primary and metastatic sites, as
well as tumor markers. Response is
also an important indicator of longterm success or cure.

Despite all this, initial resistance
(refractory) and relapse remains
the greatest cause of treatment
failure, occurring in 30 to 40 percent
of those children with high-risk
neuroblastoma. For these highrisk children with resistant and/or
relapsed neuroblastoma, there is no
proven curative therapy, although
significant translational and
clinical research is ongoing here at
Children’s Mercy for these children.
Children treated for neuroblastoma
who go on to become long-term
survivors of their cancer may have
a spectrum of disease and therapy
related sequelae. The majority have
had abdominal or thoracic surgery,

Response Definitions in Neuroblastoma Therapy
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received radiation to multiple sites,
have had ototoxic (platinums)
and cardiotoxic (anthracyclines)
chemotherapy agents and
underwent an autologous stem
cell transplant. It is imperative that
these children be followed in a longterm multidisciplinary survivorship
clinic such as Children’s Mercy’s
Survive & Thrive Clinic, to screen
for late effects as early detection
can minimize complications and
improve quality of life [See Survive
& Thrive Program]. Now with more
and more children surviving their
cancer and living into adulthood,
transitioning to adult providers
knowledgeable in these sequelae
is increasingly critical to prevent
or reduce later health
complications. The
combined program,
developed by Children’s
Mercy and the
University of Kansas
Cancer Center adult
patient providers, offers
a seamless transition
for our patients as they
become adults (as well
as for those childhood
cancer survivors
moving into our area
as adults). •

Children’s Mercy
Helps Joplin Boy Face
Neuroblastoma Head On
At just 3 years old, Martin Vu, Joplin, Mo., seemed to be a healthy, active
child, jumping and playing—and then suddenly one day he wasn’t.
“Martin started running a fever, so I took him to the doctor, but they could not
figure out what was causing it,” said Phong Vu, his father.
Over the next several days, Martin’s fever continued and his symptoms became
worse. “He was in a lot of pain,” Vu said. “His stomach hurt and he was vomiting.”
When Vu took him back to the doctor, they took X-rays and did CT scans, but still
were puzzled.
Meanwhile, Martin’s condition continued to decline. After two months of questions,
Martin was sicker than ever. His legs hurt, his back hurt, he couldn’t walk. “We needed
answers,” his father said. So Vu requested Martin be transferred to a pediatric hospital.
The first day Martin arrived at Children’s Mercy Kansas City, testing revealed why he was
getting sicker—a high-risk neuroblastoma, the most common solid tumor malignancy
outside the central nervous system
in children and a cancer that is often
diagnosed only after it has spread
widely.
“Martin was a very sick boy when he
was admitted,” said Joy L. Bartholomew,
APRN, CPON. “He had disease all over his
body.”
Now Martin and his family not only knew
what they were fighting, they knew they had
the strength and depth of one of the nation’s
best pediatric oncology teams in their corner.
But before treatment could begin, Martin had
two surgeries to place a chest tube and implant
a central line for chemotherapy and blood testing. Initially, he had two cycles of chemotherapy lasting
one week each month. After the second cycle, the team harvested his peripheral blood stem cells for
later use. When Martin wasn’t at Children’s Mercy, his blood work was monitored close to home at the
hospital’s Joplin clinic.
After three more cycles of chemotherapy, Martin had minimally invasive surgery to remove a mass the size
of an orange from his abdomen. When he recovered, Martin received a sixth cycle of chemotherapy, then a
bone marrow transplant to further target any resistant tumor remaining.
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The next month, Martin received 20
radiation treatments, followed by
six cycles of tumor-specific antibody
therapy designed specifically to
harness his immune system in the
fight against his cancer.
“Children’s Mercy was involved
in the clinical trials for immune
therapy, and has more than a
decade of experience with this
treatment,” Bartholomew said. “This
is a very intense treatment that
requires a lot of supportive care
from our team, but it has improved
survival rates for these patients from
20 percent years ago, to 60 percent
today.”
Martin is one of those survivors.
Three years after his diagnosis, he’s
in remission and his family’s lives
are returning to normal. “Martin just
celebrated his seventh birthday. He
is back in school and loves it!” Vu
said. “He is active again and enjoys
singing. He says when he grows up,
he wants to be a policeman.”
Vu, who quit his job and spent
three years caring for his son, also
has returned to work full time. The
frequent road trips from Joplin
to Children’s Mercy are now just
a memory. They only go to the
hospital every six months for checkups.
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Looking back, Vu said if he had not
asked for Martin to be transferred
to Kansas City, he’s not sure his son
would be alive today.
“The staff at Children’s Mercy had
the experience to take good care of
him. It is the best children’s hospital.
They gave Martin a chance to live
and grow up. Thank you very, very
much to the doctors and nurses at
Children’s Mercy.” •

Radiology
Imaging plays a significant role in the diagnosis, staging and posttreatment follow-up of neuroblastoma.
Because a majority of cases of neuroblastoma present as a painless
abdominal mass, ultrasound provides an excellent first-line imaging test.
Ultrasound is a quick, easily accessible and pain-free examination that uses
sounds waves instead of radiation in the production of images. Ultrasound
provides very good localization, and characterization of the mass, often
demonstrating the calcification that is present in nearly all neuroblastoma cases.
Once the diagnosis of neuroblastoma
is highly suspected, as the result of
physical exam, laboratory and initial
imaging findings, the next step from
an imaging standpoint is to further
define the tumor and the extent of
disease. This is usually accomplished
with computed tomography (CT) with
doses modified for the child’s size or
magnetic resonance imaging (MRI).
Increasingly, MRI is being utilized over
CT because of the lack of ionizing
radiation. At Children’s Mercy, childspecific protocols are in place to safely
perform scans without undue stress to
the child and are done with or without
sedation under the direction of our
sedation team and anesthesiology.
Nuclear medicine is a special division within radiology and a test called an I-123 MIBG
scan remains the favored nuclear medicine study for diagnosis, staging and follow-up of
neuroblastoma. The MIBG scan takes advantage of the fact that neuroblastoma is a tumor of the
sympathetic nervous system. MIBG, or metaiodobenzylguanidine, is a radiolabeled molecule, that
is very closely related to norepinephrine, and therefore concentrated in sympathetic nervous tissues,
such as neuroblastoma. Children’s Mercy is the only facility in the region with this specific I-123
capability. •
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Pathology
Neuroblastoma is a solid tumor
that commonly develops in
the adrenal gland or along the
sympathetic chain anywhere from
the neck to the pelvis. It arises
from the neural crest cells that are
essential in normal embryologic
development of the spinal cord.
Morphologically, it is classified
according to the degree of cell
differentiation, into neuroblastoma,
ganglioneuroblastoma and
ganglioneuroma; the latter is a
benign neoplasm. Neuroblastomas
occasionally undergo spontaneous
regression or maturation to
ganglioneuroma.
To diagnose neuroblastoma,
pathologists employ morphologic
and biochemical approaches.
Cutting through the tumor shows
soft, tan-gray tissue, often with
areas of necrosis, hemorrhage
and/or cysts. Histology ranges
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from sheets of primitive,
undifferentiated, small, round, blue
cells to mature ganglion cells in
a Schwannian stroma. Rosettes
of tumor cells may be present.
Pathologists also use immunostains
to distinguish neuroblastomas
from histological mimics,
such as rhabdomyosarcoma,
Ewing sarcoma, Wilms tumor
and lymphoma. A pathologic
classification, which takes into
account the degree of tumor
differentiation, patient’s age and
the mitosis-karyorrhexis (MKI)
index, helps stratify patients for
different therapies. This system
describes tumors as “favorable” or
“unfavorable” tumors, as defined
by the International Neuroblastoma
Pathology Committee (INPC).
Approximately 90 percent
of neuroblastomas secrete
catecholamines. Catecholamines
and their metabolites
are useful biomarkers
detectable in blood and/
or urine and include
dopamine, homovanillic
acid and vanillylmandelic
acid. When elevated
prior to treatment, these
biomarkers are used
to monitor response
to therapy and tumor
recurrence. •

Sahibu Sultan Habeebu, MD, PhD

Cytogenetics
Neuroblastoma, a malignant
pediatric cancer derived from
immature cells of the sympathetic
nervous system, is a genetically
heterogeneous tumor that accounts
for approximately 15 percent of all
pediatric cancer deaths. Genomic
alterations of neuroblastoma
strongly influence tumor behavior
and patient survival.
Diploid tumors with approximately
46 chromosomes have been long
recognized to be associated with
a less favorable outcome than
near-triploid tumors with closer to
69 chromosomes. Study of tumor

tissue genetics is accomplished by
conventional chromosome analysis,
fluorescence in-situ hybridization
(FISH), and more recently microarray
analysis and gene sequencing.
Determination of the presence
or absence of specific genomic
gains and losses, gene mutations
or amplification along with tumor
stage and differentiation, and
patient age are all factors used

to stratify patients for
therapeutic intervention.
Amplification of the
MYCN gene is associated
with high-risk tumors
independent of tumor stage
and patient age. Segmental
chromosome aberrations,
especially those involving
chromosomes 1p, 11q and
17q impact patient outcome
unfavorably. Conversely,
tumors without segmental
chromosome aberrations or
MYCN amplification are associated
with good overall survival.
Fresh neuroblastoma
tumor tissue processed
in the cytogenetics
laboratory at Children’s
Mercy is cultured for
cell growth to assess
the tumor genome for
chromosome number
and aberrations, while
fresh or fixed tumor is
used to determine MYCN
amplification status. DNA
isolated
from tumor
is used for
microarray and
sequencing. Microarray
analysis provides
high-resolution
whole genome
analysis and is the
most comprehensive
method for study
of neuroblastoma
currently available.

The recent discovery of ALK
gene activating mutations in
approximately 8 to 10 percent of
neuroblastomas has opened an
avenue for targeted therapy in
this subgroup of neuroblastoma
patients. •
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Genomics and 		
Cancer Biorepository
The Children’s Mercy Cancer Genomics Program is a team effort
between the Children’s Mercy Cancer Center and the Center for Pediatric
Genomic Medicine. The program makes next-generation sequencing
research available to all oncology patients. Any patient being treated for
neuroblastoma at Children’s Mercy may enroll in a research protocol for
genomic sequencing. Once enrolled, DNA from the patient’s healthy blood
cells and from the tumor cells are analyzed and compared. The team is
also looking at RNA and epigenetic changes in the tumor cells. All of the
genomics research work is done
at Children’s Mercy. The goal of the
work is to better understand the
cause of neuroblastoma and to
develop better treatments. In some
cases, genomic sequencing may
help clinicians choose treatments
that are targeted to a patient’s
tumor.
As part of the support for the
Cancer Genomics Program and
other research programs, the
new Cancer Center Biorepository
provides a core service within
Children’s Mercy. Patients with
neuroblastoma may opt to donate
blood, leftover tumor samples,
DNA and clinical data to the
Cancer Center Biorepository. The
donated material and clinical data
are stored in a protected database
and are available to research
scientists, with approved protocols, to study cancer and related diseases. By
participating in the Biorepository, patients with neuroblastoma provide critical
resources that are needed to make progress toward targeted treatments
and even better cure rates for future children diagnosed with cancer.
Erin Guest, MD, is the director of the Children’s Mercy Cancer Genomics
Program and co-director with Alex Kats, MD (Pathology) of the Cancer Center
Biorepository. For more information about either program, please contact the
Hematology/Oncology office at (816) 302-6808. •
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Erin Guest, MD, and Midhat Farooqi, MD, PhD

General Surgery
Over the last decade, there have been remarkable advances in the medical
management and chemotherapy protocols for children with neuroblastoma.
In parallel with these improvements, the surgical approach to children with
neuroblastoma has also changed. Even though the surgical removal of the
tumor still plays a major role in almost all of the treatment plans, we now know
that some neuroblastomas (classified as “non-high risk”) can be managed with
observation alone or with only low-dose chemotherapy. On the other hand,
surgery is still necessary for children whose tumors are “high risk.”
When surgery is required, the surgery should
be done by pediatric surgeons who are welltrained and experienced in the management of
these tumors. Advanced stage tumors can be very
complicated and difficult to remove. In order to
maximize the benefits of surgery, the operation must
always be done as a part of a larger, comprehensive
approach to treatment.
The goal of surgery is always to completely remove the
tumor and is more easily accomplished when the tumor is relatively small and has not grown
into any surrounding structures (INSS Stage 1, 2 tumors). Unfortunately, as neuroblastomas
expand (INSS Stage 3,4) they can infiltrate into any adjacent organs (e.g., kidney/liver) and/or
can encase critical blood vessels (e.g., aorta, vena cava, renal artery and vein). These surgical
obstacles can often be found on pre-operative CT scans and today are called “image defined
risk factors” (IDRF). When these IDRFs are present, complete removal of the tumor is quite difficult,
if not impossible, and complications from the tumor removal increase significantly. These IDRFs
determined at the time of diagnosis combined with critical histologic and molecular findings from
the initial biopsy has led to the most recent neuroblastoma risk classification system (INRG) now in
use. As most intermediate and high-risk neuroblastomas are not resectable at diagnosis, a closely
coordinated multi-modality approach is critical to future surgical resection capabilities.
The experienced pediatric surgeon on the team is critical to not only ultimately achieve the greatest
resection, but to also assess the timing of this — either at diagnosis or later in therapy. Pre-operative or
neoadjuvant chemotherapy is used to decrease tumor size and infiltration, allowing a greater likelihood
of successful tumor resection. Through surgical research in pediatric cancer centers such as Children’s
Mercy Cancer Center and in partnership with national organizations such as the Children’s Oncology
Group (COG), we’ve identified that when it is not feasible to fully resect the remaining tumor, a very good
partial resection of at least 95 percent of the tumor removed (without removing or injuring involved organs
(e.g., kidney or liver) or vessels (e.g., renal artery/vein or aorta/vena cava) can provide equivalent opportunity
for cure to a total resection. This is also important in light of the continuing therapy that will follow the surgery
and which includes bone marrow transplant, radiation and immunotherapy. A very closely coordinated review
with ongoing communication between the surgeon and other specialties on the neuroblastoma team allows
for the vastly improved and best long-term outcomes seen today in children with neuroblastoma. •
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Bone Marrow Transplantation
Survival for children with low-risk
neuroblastoma is greater than
90 percent with relatively less
therapies, while survival for those
with high-risk neuroblastoma
was less than 20 percent when
conventional chemotherapy, surgery
and radiation alone were used.
Resistance of neuroblastoma cells
to conventional chemotherapy
remained the main reason for
treatment failure in
high-risk patients
in the 1980s and
early 1990s. In those
years, the idea
of chemotherapy
intensification to
overcome this
through the use of
myeloablative (bone
or peripheral blood
stem cell transplant)
consolidation therapy
was pursued. Not
until the advent of
peripheral stem
cell collection and
incorporation of it
for neuroblastoma
in the early 1990s did autologous
peripheral blood stem cell
transplant (PBSCT) become a
feasible option.
A Children’s Oncology Group
trial of PBSCT vs. no PBSCT after
conventional chemotherapy, which
included Children’s Mercy patients,
showed that with transplant
progression-free survival improved
significantly to 40 percent or better.
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Subsequently, children participated
in a clinical trial that showed
repetitive use of this approach (now
called tandem transplant) resulted
in nearly a 15 percent improvement
in three-year progression-free
survival now, in excess of 60 percent
when combined with the other
therapies described in this report.
As seen throughout this report, a
well-coordinated multispecialty,

multidisciplinary approach is critical
to the child’s chances of beating
their cancer. Research such as
that described above, combined
with other studies that showed it
was better to delay the radiation
until after PBSCT rather than prior,
has led to our current paradigm of
sequential therapy used today.
It is now the standard of care to
incorporate a tandem transplant

using PBSCs after five to six cycles
of induction chemotherapy and
surgical resection subsequent to
the PBSCT, with radiation therapy
followed by six cycles of antineuroblastoma immune therapy
and differentiating agents. This very
intensive sequence of therapies
administered in a timely manner
and dealing with the myriad of
side effects that comes with it is
now achieving
survivals only
dreamed of a
few years ago.
With further
research, we
hope survivals
in the future
will continue to
improve to not
only cure all
children with
this cancer,
but to do so
without the cost
of side effects
they must
endure. •

Radiation Therapy
Over the years, the role of radiation
therapy for neuroblastoma has
evolved.
For patients with low or intermediate
risk disease, high survival rates with
surgery and/or chemotherapy are
expected, and radiation is reserved
for local recurrence.
In infants with good prognosis
disease (Ms disease), radiation has
been used only for life-threatening
conditions.
Thus radiation is reserved for
those children with high-risk
neuroblastoma. Most of the patients
that receive radiation therapy have
already had a transplant. Radiation
therapy is used to treat the site

where the tumor started and sites
that the tumor metastasized or
spread to by the bloodstream to
involve other areas of the body.
Radiation is focused treatment
and with improved technology we
are able to deliver the treatment
precisely. Over the years, national
studies have clearly shown an
improvement in the overall survival
with the addition of radiation
therapy to treat children with
high-risk neuroblastoma. Because
neuroblastoma can occur in the
chest, abdomen or pelvis, and can
spread to many other areas of the
body, the sites treated and doses
are tailored for the individual. In
order to deliver radiation therapy,
a team consisting of the physician,
nurse, physicist, therapists and
support staff work closely together.
This team works in close conjunction
with the child’s primary oncology
team, radiology and surgery to
ensure therapy is seamless and
timely. For those who require
sedation, a Children’s Mercy
pediatric anesthesiologist is on site.
The Children’s Mercy Cancer Center
works with the department of
radiation oncology at the University
of Kansas Cancer Center, a National
Cancer Institute-designated
program. •
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Antibody Therapy
Immune-mediated therapy has
revolutionized cancer treatment and
has significantly improved survival
in high-risk neuroblastoma patients
(20 percent better event-free
survival and 11 percent better overall
survival (Yu et al., NEJM 2010)) who
have had at least a partial response
to multimodal therapy.

This combination therapy has
significant side effects: severe
pain (GD2 is also present on nerve
fibers), capillary leak syndrome,
hypersensitivity reactions, fevers
and hypotension, that require
inpatient medical and nursing
expertise for prompt detection and
aggressive care management.

GD2 is a molecule on the surface
of nearly all neuroblastoma
cancer cells, and hence is an ideal
target for an antiGD2 monoclonal
antibody. Initially known as ch14.18,
dinutuximab (generic name) is given
in combination with granulocyte
macrophage colony stimulating
factor (GMCSF), interleukin 2 and
the biologic response modifier
isotretinoin (ISOT) (aka cis-retinoic
acid).

Safe administration requires the
multidisciplinary expertise offered
only in established high-volume
pediatric cancer centers. Children’s
Mercy Kansas City has been
administering this therapy for 15
years and is in the top 10 percent
of experienced treatment centers
nationally. Children’s Mercy is
currently participating in a Phase
IV study assessing immunogenicity
in patients receiving dinutuximab
treatment, and in a Phase III study
assessing efficacy in refractory or
relapsed neuroblastoma. •

This treatment is delivered in
a maintenance phase, which
follows the consolidative therapy
of tandem hematopoietic stem cell
transplantation and radiation. It
consists of five alternating cycles
with a sixth cycle solely of ISOT.
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Children’s Mercy Kansas City
has been administering this
therapy for 15 years and is in the
top 10 percent of experienced
treatment centers nationally.

Cancer Immunotherapy Program
The Children’s Mercy Cancer Center
Immunotherapeutics Program is a
relatively new project, focused on
building infrastructure and regional
collaborations of like-minded
investigators.
The program began with the
region’s first trial of genetically
modified T-cells expressing a
chimeric antigen receptor (CAR)
targeting GD2 in patients with
neuroblastoma. At the time, this
trial placed the hospital and region
among a select few capable of
investigator-initiated trials of this
kind. It also established ongoing
collaboration with the Center for Cell
and Gene Therapy at Baylor College
of Medicine, where the cells were
produced. A similar trial of GD2
CAR expressing T-cells targeting
melanoma in adults was designed
at Children’s Mercy and is open and
ready to enroll.

Experience in this form of complex
therapy was of interest to
pharmaceutical companies, such
as Novartis, when they intended
to open the first multi-institutional
study of CAR targeting
CD19 in pediatric patients
with acute lymphoblastic
leukemia. The trial is ongoing
at Children’s Mercy.

to study new CAR constructs in
well-established in-vitro models
and novel immunocompetent
animal models. Initial efforts at CAR
constructs were presented and

In summary, the clinical trials
portion of the program is
robust. We are now focused
on establishing the basic
science and translational
laboratories essential to
conducting these clinical
trials.
While conducting and
participating in complex gene
transfer studies, efforts are ongoing
to expand the field of cellular
immunotherapeutics and complex
biologics in the region.
The program is
actively reaching out
to investigators at the
University of Kansas,
Kansas State University,
University of Missouri,
and Kansas City Area
Life Sciences Institute.
A Midwest Cancer
Alliance grant funds a
collaboration between
Children’s Mercy, KU
Medical Center and
Kansas State University

well-received at the 2016 American
Society of Gene and Cell Therapy
meeting in Washington D.C. We will
reach out further in an upcoming
effort, Collaborate2Cure, sponsored
by the Kansas City Area Life
Sciences Institute.
It is the intention of the program
to dovetail with the goals and
aspirations of the developing
Children’s Mercy Research Institute
and work synergistically with the
immunotherapy interests and efforts
of others in the region. We intend
to develop other forms of cancertargeting immunotherapeutics
and apply lessons learned beyond
the field of cancer to immune
dysfunction and autoimmunity. •
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Experimental
Therapeutics
Standard therapy for high-risk neuroblastoma is the most comprehensive
and aggressive treatment used to treat any cancer. Newly diagnosed
children with high-risk neuroblastoma receive treatment with chemotherapy,
surgery, two autologous hematopoietic stem cell transplants, radiation
therapy and immunotherapy. Despite this approach, a long-term cure is
expected for only 50 to 60 percent of children. For patients with relapsed
disease or for those that progress while on therapy, new and innovative
treatments are desperately needed.
The Experimental Therapeutics in Pediatric Cancer Program brings early
phase clinical trials to patients at Children’s Mercy Kansas City. For children
with neuroblastoma who are not cured with initial therapy, there are a
number of phase 1 and 2 trials that provide access to the newest and most
promising treatments. As members of the Children’s Oncology Group and
the Neuroblastoma and Medulloblastoma
Translational Research Consortium, we are a
part of groundbreaking research, striving to
transform new information about how cancer
cells function into new therapies. Locally, the
ET researchers are focusing on new drug
discovery, drug repurposing and reformulation,
pediatric-specific pharmacokinetics and
modeling, and pharmacogenomics in
collaboration with both the KU Cancer Center
and Children’s Mercy Clinical Pharmacology
Program, one of the largest in the country.
The Experimental Therapeutics Team at
Children’s Mercy includes three physicians, an
advanced nurse practitioner, a social worker
and four clinical research coordinators. •

Keith August, MD, MS
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Helping Jaelee Fight
Neuroblastoma with
Everything She Has
The first sign that 6-year-old Jaelee Munson of Quapaw, Okla., might be
sick was a persistent low-grade fever. “She started running a 100-degree
fever almost every day in the spring of 2015,” said Casie Munson, Jaelee’s
mom. “I carried acetaminophen with me everywhere I went.”
A few months later, Jaelee was diagnosed with mononucleosis, explaining the
fevers and constant fatigue. Then her stomach began to swell. “I went to give
Jaelee a bath one day and noticed her side was sticking out,” Casie said.
When a CT scan revealed a cantaloupe-sized tumor, the family’s primary care
provider suspected cancer and asked whether they would like to go to Oklahoma
City or Kansas City for Jaelee’s care.
“I asked him, ‘If Jaelee were your child, where would you want her to be treated?’”
Casie said. “He didn’t hesitate, ‘Children’s Mercy.’” The hospital accepted her transfer
immediately, and when Jaelee arrived, the cancer team went to work determining her
diagnosis, then developing a treatment plan.
“When we got to Children’s Mercy,
we felt like we were in the right place,”
Casie said. Five more days of testing
confirmed that the tumor in Jaelee’s
abdomen was on her adrenal gland,
and disease had spread throughout her
bone marrow. She had high-risk metastatic
neuroblastoma.
“We were finally getting answers,” Casie said.
“We were ready to fight. All I could think is,
‘Cancer isn’t taking my child!’”
The first phase of treatment involved five rounds
of chemotherapy. Jaelee was hospitalized for
each with her parents staying by her side.
After completing every round, Jaelee and her family returned to Quapaw, but only briefly. “Jaelee
would have fevers while her immune system was down,” said Kevin Munson, her father. “She’s been
transported to Children’s by air and ground ambulance three times since April.”
The fevers and infections lengthened the time needed for her body to recover between treatments, but
Jaelee stayed strong. By summer, she was posing for the Children’s Mercy calendar, and in August, doctors
removed the tumor.
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Following surgery, Jaelee developed
a hematoma that required two
drains be implanted to remove
the blood accumulating in her
abdomen. Then she received an
additional round of chemotherapy.
Now in the midst of her treatment
plan, she’s preparing for two bone
marrow transplants, followed by
radiation and finally, tumor-specific
antibody therapy.
During Jaelee’s treatment, the family
has faced other hardships. Their
home in Quapaw recently caught
fire while they were in Kansas City;
Casie lost her job because she
missed too much work while caring
for her daughter; and the family
put so many miles on their vehicle
making the 200-mile trip to the
hospital, they had to get a new one.
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Still, Children’s Mercy has been at
their side. “When our house caught
on fire, our social worker connected
us to the Red Cross,” Casie said.
And because she’s been sick for
so long, the hospital’s on-site
school teacher has been helping
Jaelee keep up with her first-grade
assignments.
Soon, Casie and Kevin hope their
daughter will be back in school,
playing outside and cruising around
the yard in her Barbie jeep.
Until then, Jaelee is fighting cancer
with every resource Children’s Mercy
has available.
“Everyone is very kind and
considerate here. Plus, they know
exactly what they are doing,”
Kevin added. “This place is
awesome.” •

Advanced Practice
Providers
Children with neuroblastoma require multiple physician subspecialists;
pediatric oncologists, surgeons, anesthesiologists, radiation oncologists
and bone marrow transplant physicians. Care extends beyond the medical
team to include nurses, social workers, Child Life specialists, chaplains and
nutritionists. The advanced practice provider is an instrumental part of the team
and facilitates the coordination of care. Each child has a primary oncologist,
an advanced practice provider and a social worker from the time of diagnosis.
The child’s primary advanced practice provider is the point person for all patient
contact and interacts with the various members of the team to ensure all medical
and supportive service needs are met. The primary advanced practice provider also
provides education, reviews therapy and its affect on the child, performs physical
exams and orders laboratory tests, scans and prescriptions. The child’s primary
advanced practice provider helps their patient and family navigate the complex
world of medical care necessary for their best chance at a cure for their cancer.
Inpatient advanced practice providers care for patients during each chemotherapy and
immunotherapy admission and during bone marrow transplantation. The advanced
practice provider care model provides personalized,
efficient and coordinated care for Children’s Mercy
oncology patients. •

Joy Bartholomew, APRN, CPON
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Oncology Nursing - Sites of Care
Outpatient Clinic – Children’s
Mercy Adele Hall Campus
The Hematology/Oncology Clinic
provides a multidisciplinary
approach in caring for children and
their families with neuroblastoma.
During an appointment, the child is
seen in one of our 18 exam rooms
by a care assistant, a registered
nurse, physician and or advanced

questions, providing education,
and screening for disease and
treatment-related side effects. They
readily contact the providers when
needed.
The clinic has 11,000 visits a year
with each child cared for by a
registered nurse certified in pediatric
advanced life support. Due to the
intensive needs of children with
neuroblastoma, they will have
many weekly and even daily clinic
visits throughout their therapy.
These children develop strong
relationships with our nurses and do
not hesitate in coming to their clinic
appointments.
For those in the Joplin region, we
offer monthly access to off-therapy
exams and labs staffed by our
Hematology/Oncology staff and
physicians.

Inpatient Unit – 4 Henson-Hall
– Children’s Mercy Adele Hall
Campus
practice nurse, a social worker — all
primary providers — along with a
Child Life specialist, a nutritionist or
pharmacist, depending on the care
needs of the day.
The clinic also has 14 infusion rooms
where highly skilled registered
nurses assess the child, obtain
laboratory specimens, administer
chemotherapy and transfuse blood
products. The registered nurses are
the front line in answering parent
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Children’s Mercy has a designated
38-bed Hematology/Oncology
unit for inpatient stays, of which
15 rooms are specially designed
for bone marrow transplant. The
majority of high-risk neuroblastoma
therapy is given in the hospital
setting: chemotherapy, tandem
transplant and immunotherapy.
Each registered nurse on the
floor has undergone specialized
education and training in this
disease, its treatment and sideeffect management. Overseeing

this therapy is our chemotherapy
service staffed by advanced
practice nurses. These professionals
are well-versed in all the cancer
treatment plans and therapy side
effects. The number of high-risk
neuroblastoma patients treated
each year at Children’s Mercy and
the quality of registered nurse
and advanced practice nurse care
affords us the experience to be
experts in the delivery of complex
therapy such as monoclonal
antibody therapy.

BMT Unit and Clinic
The initial therapy plan for
all children with high-risk
neuroblastoma includes a tandem
transplant. Due to the complex
needs of these children, the
thorough assessments provided
by our skilled registered nurses are
even more critical. As such, there
are set qualifications with additional
education requirements in order to
become a BMT nurse. At times, the
care provided is so intricate that
a BMT registered nurse may have
only one patient. Transplanting 35
to 40 children at Children’s Mercy
each year, these BMT nurses are
experts in delivering safe, quality,
complex care. Advanced practice
providers specialized in transplant
also oversee the child with high-risk
neuroblastoma. These providers
manage care, both inpatient and
outpatient, assuring a high standard
of care while providing a seamless
transition between venues. •

Psychosocial (FaCT) Services
Multidisciplinary care is integral to the overall outcomes and well-being of our patients. Outside of medically
directed care, patients and families have many other needs that are addressed by our Family Care Team (FaCT).
Regular FaCT rounds and collaboration ensures that all physical, developmental, emotional, educational and
spiritual needs are met for our patients and families. The Family Care Team is available to assist from point of
diagnosis through the completion of treatment and beyond.
Child Life Specialists promote a
positive environment for patients
and families based on their
needs. This is accomplished by
providing materials and guidance
for developmentally appropriate
play, preparing children for
medical experiences, advocating
for patient and family rights, and
promoting a non-threatening
environment. Our team tries to
reduce stress and worry that may
come with being in the hospital
or from being ill. We help children
deal with their feelings, thoughts
and questions. We provide
services to help children continue
to learn and grow while in the
hospital. Our team members
encourage patients to interact
with other children.

The Parent to Parent Program (PTP) continues to offer support and
comfort to all of our families through the use of inpatient parent
volunteers, parent rooms, Peer Match Program, and the bereavement
follow-up program. There are many services offered through the PTP
program including trained parent volunteers available to share, listen
and support our current parents; two stocked parent rooms on the
inpatient unit that offers weekly dinners, breakfasts, therapeutic and
educational activities and a safe place to unwind while a child is an
inpatient; and “care bags” for new families upon admission to help
ease some burden of a hospital stay. The PTP program also offers an
extensive bereavement follow-up program that supports families for
approximately 13 months after a child’s death. We have successfully
introduced social media into our bereavement follow-up program
and have been able to offer additional support in that way. The PTP
program manager coordinates and manages a number of grants that
provide support to patients and families including lunch and learns and
new parent journals.

Clinical social workers are master’s-level licensed professionals working as part of
the primary team to provide comprehensive and compassionate family-centered
care. Social workers understand that any change in the child’s health can alter
a family’s life in many ways, and are trained to provide a thorough assessment
and address the needs of the patients and families. Social workers can help with
therapeutic support including adjustment to illness, crisis intervention, development
of coping skills, family concerns, end-of-life and bereavement; care planning
including education on advance directives, school concerns, legal issues, transition to
adult care and end-of-life concerns; and community/resource referrals to assist with
financial concerns, transportation and lodging needs, support and mental health
referrals. Every patient has an assigned clinical social worker who follows the patient
and family through diagnosis, treatment, relapse, survivorship or bereavement.
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The Hematology/Oncology Division
has two psychologists to assist
patients and families with coping
with the diagnosis and treatment of
neuroblastoma and other cancers.
They are available to meet with
patients and their families both
while hospitalized and when as
outpatients. In addition to therapy
services, the psychologists are also
able to complete neurocognitive
evaluations to assess any impact
of medical treatment on brain
functioning and to assist with
school re-integration and planning.

The chaplain working with Hematology/Oncology/BMT
is available to meet and provide spiritual and emotional
support for patients and families during the course of the
child’s illness, as end-of-life discussions are necessary, at
the time of death and beyond. The chaplain can assist in
contacting a family’s own clergy if requested, or locating
a local clergy of the patient/family’s denomination or faith
for families who are not from the area. The chaplain also
provides education on spiritual resources and support
available within the hospital, including the chapel, worship
opportunities and special events. The chaplain regularly
participates in hematology/oncology rounds. The chaplain
also provides support to members of the staff.

An on-site school
teacher works with
patients primarily on
the inpatient floor,
with some availability
in clinic as needed
to assist with the
challenge of keeping up with school work while a
patient is undergoing treatment. Our school teacher
is able to communicate directly with the child’s
school to obtain current assignments and also to
advocate for the patient’s needs once they return to
the school setting.

Pet therapy is our newest modality
to help our patients’ and families’
psychosocial needs while battling to
beat their cancer. While visiting pets
have been available for many years,
last year Children’s Mercy hired two
new employees — Hunter and Hope —
who are full-time canine employees of the hospital along with their full-time
handlers. These wonderful, specially trained canines spend hours five days a
week helping our children by delivering comfort, cheer and day-brightening
tail wags. Hunter is stationed on the Hematology/Oncology inpatient unit
when at work and can be found walking the halls or lying in bed, accepting
belly rubs or just providing a kind shoulder or paw to rest upon.
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Music therapy services are offered
to patients and families at the
bedside to address the specific
needs of each individual patient.
Music interventions are designed
after an assessment of need
and generally involve the use of
both live vocal and instrumental
music, as well as technology.
Goals may include but are not
limited to the reduction of pain or
anxiety; increased self-expression,
movement or relaxation; and the
support of developmental skills.
Patients are encouraged to take
an active role in making music and
learning how to use music as a
helpful and fun tool.

Pharmacy
The Pharmacy is integral to the complete care of oncology patients.
Distinct teams within the Pharmacy include decentralized pharmacists,
clinical specialist pharmacists, investigational drug service, home care and
outpatient operations. We have three clinical pharmacy specialists who work
with Hematology/Oncology patients and assist the primary care team in
optimizing patient medications based on drug interactions, disease states
and organ function.
In addition, we have four pharmacists and a technician dedicated to the
review of chemotherapy orders and who are responsible for the safe
production and distribution of chemotherapy to all patients within Children’s
Mercy. These additional pharmacists, like the pharmacy specialists, are part
of the interdisciplinary rounding teams caring for inpatients. They may also
spend part of their day educating both inpatient and outpatient families.
Our investigational drug service works with more
than 130 open drug studies for our patients, including
phase I and II oncology drug studies. We have three
pharmacists and a technician dedicated to providing
clinical pharmacy support and research study services
for all active research studies. The clinical pharmacists
also provide educational materials to our nursing staff to
ensure the best care is provided to our patients involved
in drug trials. Our outpatient pharmacy is available to
compound many prescriptions that are not commercially
available and provide care to patients as they transition
to home.
Our Hematology/Oncology pharmacists are dedicated
to providing education to pharmacy students through
clinical rotations and lectures at our local schools of
pharmacy. Children’s Mercy has a nationally accredited
post-graduate pharmacy residency program. •
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Nutrition
Children with newly-diagnosed neuroblastoma have a complex medical
picture requiring thorough assessment of their baseline nutritional status
and immediate nutrition needs, as well as formulation of a careful plan for
nutrition supplementation.
Forming a trusting relationship with families from the start helps dietitians
move swiftly to help families and children cope with: the needs of the
child despite medical complications; the stages of grief; and new social
complexities with which families must cope. Neuroblastoma complicates
nutritional assessment due to the typical presence of a large abdominal
mass, which often compresses stomach capacity, contributing to decreased
appetite and critical organ compression even before other disease
symptoms manifest.
At times, tumors must be reduced with chemotherapy for several days
in order to relieve burdened organ systems, allowing a child to tolerate
nutritional support, such as naso-gastric tube feedings or intravenous
parenteral nutritional support. These large tumors also skew assessment of
a child’s weight, which further complicates nutritional assessment.
At Children’s Mercy, pediatric clinical nutrition specialists utilize additional
tools to properly identify malnutrition, such as the Nutrition-Focused Physical
Exam. This process involves a comprehensive hands-on assessment of
patients, including measuring the mid-upper arm circumference to identify
signs of malnutrition and nutrient deficiencies or toxicities. Children are
assessed upon diagnosis, and throughout treatment.
Nutrition care plans are tailored to each family’s schedule and overall
needs, with the child and family functioning as integral members of the
multidisciplinary team.
Chemotherapy side effects of neuroblastoma treatment can significantly limit
children’s ability to support themselves with food and fluids, necessitating a
feeding tube.
Childhood malnutrition can have far-reaching consequences if not corrected
promptly. Thus, registered dietitians are crucial members of the team. •
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At Children’s
Mercy, pediatric
clinical nutrition
specialists
utilize
additional tools
to properly
identify
malnutrition,
such as the
NutritionFocused
Physical Exam.

Survive & Thrive
care providers in other specialties
to ensure each survivor’s unique
health needs are met.

The program sees, on average,
200 survivors a year. Survivors are
at risk for late effects from their
cancer and treatment. Late effects
of treatment can be physical or
emotional and typically appear
in the second decade of life. The
development of late effects may be
influenced by the type of cancer,
the treatment, age at diagnosis and
genetic predisposition. An estimated
75 percent of childhood cancer
survivors will develop at least one
late effect at some point during their
life. Late effects may be preventable
or modifiable, which is why yearly
lifelong follow-up is important for all
survivors.

The Survive & Thrive team has
worked closely with the Midwest
Cancer Alliance, University of
Kansas Hospital and University of
Kansas Cancer Center to develop
the Survivorship Transition Clinic.
The clinic sees childhood cancer
survivors who are at least 18 years
old and is one option survivors have
when deciding where to continue
their follow-up care
as adults. The Survive
& Thrive team works
with each survivor
to develop a plan
for their follow-up
care after they are 21
years old. The goal
is to provide each
survivor and the adult
providers with the
information needed
to ensure continued
follow-up care and
monitoring for late
effects.

A visit to the Survive & Thrive Clinic
includes a thorough physical exam,
recommendations for long-term
follow-up care, education on late
effects of cancer treatment and
how to maintain a healthy lifestyle.
Included in the visit are nutritional
and psychosocial assessments. As
survivors reach the teenage years,
preparation for transition to adult
providers is incorporated into each
visit. The Survive & Thrive team
works with each survivor to help
them learn how to advocate for their
health care needs once they leave
the pediatric setting.

Examples of late effects that may
occur in survivors with a history of
neuroblastoma include hearing
loss, heart dysfunction, infertility
and development of a second
cancer. In the Survive & Thrive Clinic,
survivors will be monitored for
development of late effects based
on the treatment they received
and according to the Children’s
Oncology Group Long-term Followup Guidelines. The team will
ensure any recommended testing
is performed and will monitor
those results. The Survive & Thrive
team works closely with health

learn more about specific topics
related to survivorship, and reach
survivors who may not be aware of
their health risks.

The Survive & Thrive Program
started in 2009 to offer
comprehensive medical and
emotional care to childhood cancer
survivors who are at least two years
off treatment and five years from the
date of diagnosis.

In addition to clinic, the Survive &
Thrive team hosts a conference for
young adult survivors of childhood
cancer called “I Beat Cancer… Now
What?” The goal of the conference
is to bring together young adult
survivors to connect with each other,

Joy Fulbright, MD, and Kyla Alsman,RN, BSN

The Survive & Thrive Program exists
to meet the needs of childhood
cancer survivors through clinic visits,
educational and social activities.
The goal is to ensure each survivor
seen in the clinic is aware of their
health risks, has an individualized
follow-up plan, and has help with
transitioning care to adult
providers. •
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Research and Data
Management
Research in pediatric cancer has been the driver of improving cure rates
since the 1960s. Today, the Children’s Oncology Group leads the effort with
more than 200 member hospitals enrolling patients in more than 70 active
studies.
Children’s Mercy has more than 50 of these studies available for children with
newly diagnosed and recurrent cancers. The availability of a treatment study or
a biology study allows a family a choice to participate in finding new and better
ways to treat childhood cancer.
Beginning in the late 1990s, Children’s
Mercy was one of the only institutions
to participate in the Phase 1 study of
the monoclonal antibody, ch14.18,
in patients with neuroblastoma. The
positive results of this study led to
the opening of a groupwide Phase 3
study in 2001, and the ultimate FDA
approval of the new drug. Today, we
continue to have research studies open
from Children’s Oncology Group, the
Neuroblastoma and Medulloblastoma
Translational Research Consortium,
industry sponsors, and even studies
designed by our own investigators.
Whether it is new drugs, new testing
or investigations in quality of life
or survivorship, research requires multiple steps before it can be offered to our patients and
families. Within the Cancer Center, seven research professionals are dedicated to opening new
studies and seeing that quality data and specimens are submitted on each of our studies. Their
role includes submitting research to our institutional ethics board, answering inquiries, extracting
medical information from clinical records, coordinating biological specimen collection and shipping,
consenting families to research, and overseeing the adherence to research plans. By working closely
with physicians, advance practice nurses, and others throughout the hospital and beyond, our research
program makes us highly ranked among pediatric oncology programs.
Trials currently available at or through Children’s Mercy for children with cancer can be found by at:
https://www.childrensmercy.org/cancer-clinicaltrials •
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Pediatrics, University of Missouri-Kansas
City School of Medicine

Alan S. Gamis, MD, MPH
Associate Division Director, Section of
Oncology; Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine;
Co-Director, Drug Discovery, Delivery and
Experimental Therapeutics Program,
University of Kansas Cancer Center

Rakesh K. Goyal, MD
Associate Division Director, Section of
Bone Marrow Transplantation; Associate
Professor of Pediatrics, University of
Missouri-Kansas City School of Medicine

Faculty

Ibrahim A. Ahmed, MD, DSc
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Keith J. August, MD, MS
Pediatric Hematology/Oncology; Program
Director, Leukemia and Lymphoma
Program; Interim Director, Experimental
Therapeutics in Pediatric Cancer; Children’s
Mercy Principal Investigator, Children’s
Oncology Group; Assistant Professor of
Pediatrics, University of Missouri-Kansas
City School of Medicine

Margaret A. Boyden, MD
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Katherine M. Chastain, MD
Bone and Soft Tissue Program Director;
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

45 | childrensmercy.org/cancer

Terrie G. Flatt, DO

Michelle Manalang, MD

Program Director, Spanish Speaking
Program; Assistant Professor of Pediatrics,
University of Missouri-Kansas City School of
Medicine

Medical Director, Liver Tumor Program;
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Joy M. Fulbright, MD
Program Director, Survive & Thrive Program;
Program Director, Adolescents and Young
Adult Program; Associate Professor of
Pediatrics, University of Missouri-Kansas
City School of Medicine

Kevin F. Ginn, MD
Neuro-oncologist; Program Director, Brain
Tumor Program; Assistant Professor of
Pediatrics, University of Missouri-Kansas
City School of Medicine

Erin M. Guest, MD
Program Director, Cancer Genomics
Program; Director, Cancer Center
Biorepository; Assistant Professor of
Pediatrics, University of Missouri-Kansas
City School of Medicine

Carla McCrave, MD
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

G. Doug Myers, MD
Cellular Therapy Program Director;
Associate Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Mohamed A. Radhi, MD
Associate Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Melissa S. Rayburg Jefferson, MD
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Glenson Samuel, MD
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

J. Allyson Hays, MD

Mukta Sharma, MD, FAAP, MPH

Histiocytic Disorders Program Director;
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Maxine L. Hetherington, MD
Membership Chair, Children’s Oncology
Group; Associate Professor of Pediatrics,
University of Missouri-Kansas City School of
Medicine

Gary L. Jones, DO
Assistant Professor of Pediatrics, University
of Missouri-Kansas City

Ram V. Kalpatthi, MD
Associate Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Karen B. Lewing, MD
Fellowship Program Director; Associate
Professor of Pediatrics, University of
Missouri-Kansas City School of Medicine

Michael S. Silvey, DO
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Nazia Tabassum, MBBS
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Jaszianne Tolbert, MD
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Melanie A. Villanueva, DO
Assistant Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Brian Wicklund, MDCM, MPH
Director, Coagulation Medicine Program;
Associate Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine

Cancer Care
Committee
Board Members

Medical Staff Members
Pablo Aguayo 				Surgery
Atif Ahmed, MD				Pathology
Ibrahim Ahmed, MD				Hematology/Oncology
Walter Andrews, MD				Surgery
Pablo Angulo, DO				
Hematology/Oncology Fellow
Keith August, MD - Assistant Chairman		
Hematology/Oncology
Margaret Boyden, MD			
Hematology/Oncology Hospitalist
Julia Broussard, MD				Endocrine
Katherine Chastain, MD			
Hematology/Oncology
Linda Cooley, MD				Cytogenetics
Lynne Covitz, PhD				
Developmental Medicine
Terrie Flatt, DO				Hematology/Oncology
Kristin Fickenscher, MD 			
Radiology
Jason Fraser, MD				Surgery
Joy Fulbright, MD				Hematology/Oncology
Alan Gamis, MD, MPH - Chairman
Hematology/Oncology
Kevin Ginn, MD 				
Hematology/Oncology
Paul Grabb, MD				Neurosurgery
Erin Guest, MD			
Hematology/Oncology
Nathan Hall, DO				
Hematology/Oncology Fellow
Kim Hartman, MD				
Rehabilitation Medicine
Allyson Hays, MD				
Hematology/ Oncology
Richard Hendrickson, MD 			
Transplant Surgery		
Maxine Hetherington, MD
		
Hematology/Oncology
Gregory Hornig, MD				Neurosurgery
Usiakimi Igbaseimokumo, MD			
Neurosurgery
Melissa Jefferson, MD			
Hematology/Oncology Hospitalist
Gary Jones, DO				Hematology/Oncology
Ram Kalpatthi, MD				Hematology/Oncology
Christian Kaufman, MD 			
Neurosurgery
Karen Lewing, MD				Hematology/Oncology
Jennifer Linebarger, MD			
Palliative Care
Michelle Manalang, MD 			
Hematology/Oncology
Vickie Massey, MD				
Radiation Oncology
Doug Myers, MD 				
Stem Cell Transplant
Robin Onikul, DDS				
Pediatric Dentistry
Lorien Paulson, MD				ENT
Mohamed Radhi, MD			
Stem Cell Transplant
Naresh Reddivalla, MD			
Hematology/Oncology Fellow
Sripriya Raman, MD				Endocrine
Ashish Risal, DO				
Hematology/Oncology Fellow
Glenson Samuel, MD 			
Hematology/Oncology Fellow
Mutka Sharma, MD				Hematology/Oncology
Mike Silvey, DO				Hematology/Oncology
Vivekanand Singh, MD			
Pathology		
Nazia Tabassum, MD			
Hematology/Oncology
Cindy Taylor, MD				Radiology
M. Thompson, MD				
Radiology Oncology
Jaszianne Tolbert, MD			
Hematology/Oncology
Melanie Villanueva, DO			
Hematology/Oncology
Gerald Woods, MD				Hematology/Oncology
Non-Physician Members
Jill Anderson, RN, MSN, PCNS			
Hematology/Oncology
Sarah Anderson 				
Child Life
Joy Bartholomew, RN, FNP, CPON		
Hematology/Oncology		
Constance Deverill, R.Ph			
Pharmacy
Kendra Engleman, MS			
Genetics Counselor
Katie Foote 				
Psychosocial Services
Nancy Green, Sr. CNS			
Nutrition
Diana Healy, APRN, BC 			
Hematology/Oncology
Claudia Hubbard, M. Div, BCC			
Chaplain
Jennifer Hudson, RN, MSN, CPNP 		
Hematology/Oncology
Cheri Hunt, Sr. Vice President/Chief Nursing Officer Patient Care Services/
Kristy Hurst, RHIT				Registry		
Rebecca Kahler, MSN, APN, FNP,BC,ONC		
Hematology/Oncology
Kris Laurence, CCRP				Hematology/Oncology
Jenny Marsh, RN, CPON 			
Hematology/Oncology
Wendy McClellan, RN, BSN			
Hematology/Oncology
Karen Ollek, CCRP				Hematology/Oncology
Kelly O’Neill, RN, BSN, CPON 			
Hematology/Oncology
Lisa Peters, LMSW				Hematology/Oncology
Angela Putnam, CCRC			
Hematology/Oncology
Caitlin Reinert, MS				
Genetics Counselor
Robin Ryan, MPH, CCRP			
Hematology/Oncology		
Susan Stamm, RN, MSN, PNP			
Hematology/Oncology
Kristin Stegenga, PhD, RN, PCNS, CPON		
Hematology/Oncology
Cindy Thompson, CTR			
Cancer Registry
Theresa Torres, APRN, FNP, CPHON		
Hematology/Oncology
Amanda Trout, LCSW				Hematology/Oncology
Amanda Woelk, CCLS			
Child Life
Jennifer Wulfert, RN, MSN, CPNP		
Hematology/Oncology
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Pablo Angulo, DO

CONTRIBUTORS
Alan Gamis, MD, MPH – Editor

Erin Guest, MD – Genomics

Kristy Hurst – Tumor Registrar

Keith August, MD, MS – Experimental
Therapeutics

Joy Bartholomew, MSN, RN, FNP-BC,
CPON – Co-editor
Atif Ahmed, MD – Pathology
Sahibu Habeebu, MD, PhD, FCAP Pathology
Jason Tobler, MD - Radiology
Lisa Peters, LMSW, LCSW – FaCT
Richard Hendrickson, MD – Surgery
Linda Cooley, MD, MBA - Cytogenetics
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Wendy Hein, RN, MSN, CPNP – Survive &
Thrive
Mohamed Radhi, MD – Bone Marrow
Transplant
G. Doug Myers, MD – Cellular Therapy
Robin Ryan, MPH, CCRP
Olivia Scheuerman, MS, RD, LD - Nutrition
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